Theranos and COVID-19 Testing Are Mirror-Image Cautionary Tales
By Benjamin Mazer,
The Atlantic
| 09. 15. 2021
Photo by Steve Nomax on Unsplash
Last week, prosecutors and defense attorneys made opening statements in the criminal trial of Elizabeth Holmes, the former CEO of Theranos, who is accused of defrauding investors and patients with false promises of cheap, rapid blood tests. The next day, the Biden administration announced a plan to purchase 280 million cheap, rapid COVID-19 tests—an action for which some lawmakers have been advocating for more than a year. The serendipity of these two events exposes an unresolved tension in health care: How do we balance the risks of disruptive innovation with the mortal costs of administrative inertia?
Theranos and COVID-19 testing are both cautionary tales of failed medical oversight, but the morals flip from one case to the other. Each addresses, in its way, how much control the FDA should exert over laboratory tests before they come to market. COVID-19 testing epitomizes the agency’s risk-averse instincts. In the first months of the coronavirus pandemic, the FDA notoriously delayed private labs from developing their own COVID-19 tests. This allowed the coronavirus to spread mostly...
Related Articles
By Megan Mineiro and Caroline Kitchener, The New York Times | 10.05.2025
Kathleen Whipple and her husband had dreamed of a big family, but struggled to conceive.
Upon his return from an overseas deployment with the Navy, the couple learned from a fertility doctor that her husband’s sperm count was half of...
By Karin Hammarberg, Alex Polyakov, Catherine Mills, and Karinne Ludlow, The Conversation | 10.03.2025
Reports of several cases of embryo and sperm mix-ups have put the Australian fertility industry in the spotlight for all the wrong reasons.
These bungles have raised serious questions about the industry’s current model of self-regulation, and demonstrate a lack...
By Karin Hammarberg and Catherine Mills, BioNews | 10.13.2025
The Australian fertility industry has been rocked by several recent cases of embryo and sperm mix-ups. With a lack of transparency about what clinics do to prevent such errors recurring, trust and confidence in the industry and how it is...
By Katherine Bourzac, Nature | 09.25.2025
A judge in New York rejected a request on 23 September to disqualify the use of cutting-edge DNA sequencing as evidence in a case against an alleged serial killer. The ruling paves the way for a type of DNA analysis...